Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
BRCA mutation status
Description:
The presence or absence of a pathogenic mutation in BRCA genes, used to characterize cancer and guide clinical management.
Primary topic:
PARP inhibition in cancer therapy (43%)
Related topics:
PARP inhibition in cancer therapy (43%),
Ovarian cancer diagnosis and treatment (25%),
BRCA gene mutations in cancer (11%)
OpenAlex ID:
keywords/brca-status
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
·
Jonathan Ledermann
, Philipp Harter
, et al.
·
The Lancet Oncology
·
1,580
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
2018
·
Sibylle Loibl
, Joyce O'Shaughnessy
, et al.
·
The Lancet Oncology
·
830
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
2019
·
Panagiotis A. Konstantinopoulos
, Steven Waggoner
, et al.
·
JAMA Oncology
·
609
PDF
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
2016
·
John R. Webb
, Katy Milne
, et al.
·
Gynecologic Oncology
·
371
PDF
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
2016
·
M.K. Wilson
, E. Pujade-Lauraine
, et al.
·
Annals of Oncology
·
312
PDF
The systemic treatment of recurrent ovarian cancer revisited
2021
·
T. Baert
, A. Ferrero
, et al.
·
Annals of Oncology
·
182
PDF
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
2017
·
Jason. P.W. Carey
, Cansu Karakas
, et al.
·
Cancer Research
·
160
Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months
2018
·
Stefania Rizzo
, Francesca Botta
, et al.
·
European Radiology
·
138
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity
2010
·
D.J. Gallagher
, J.A. Konner
, et al.
·
Annals of Oncology
·
126
Artificial Intelligence–Based Classification of Breast Lesions Imaged With a Multiparametric Breast MRI Protocol With Ultrafast DCE-MRI, T2, and DWI
2019
·
Mehmet U. Dalmiş
, Albert Gubern-Mérida
, et al.
·
Investigative Radiology
·
125
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
2019
·
Sudeep Gupta
, Shona Nag
, et al.
·
Journal of Ovarian Research
·
122
PDF
Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database
2016
·
J. Alejandro Rauh-Hain
, Alexander Melamed
, et al.
·
JAMA Oncology
·
111
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
2011
·
Tamar Safra
, Lucia Borgato
, et al.
·
Molecular Cancer Therapeutics
·
98
Treatment of recurrent epithelial ovarian cancer
2019
·
Sandro Pignata
, Carmela Pisano
, et al.
·
Cancer
·
96
PDF
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status
2019
·
Federica Tomao
, Erlisa Bardhi
, et al.
·
Cancer Treatment Reviews
·
93
Biomarkers for Homologous Recombination Deficiency in Cancer
2021
·
Svenja Wagener-Ryczek
, Sabine Merkelbach-Bruse
, et al.
·
Journal of Personalized Medicine
·
87
PDF
High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes
2017
·
Stephanie Nougaret
, Yulia Lakhman
, et al.
·
Radiology
·
79
Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer
2018
·
Andreas Meier
, Harini Veeraraghavan
, et al.
·
Abdominal Radiology
·
76
PDF
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
2022
·
Panagiotis A. Konstantinopoulos
, Jung-min Lee
, et al.
·
Gynecologic Oncology
·
70
PDF
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
2021
·
Francesca Bizzaro
, Ilaria Fuso Nerini
, et al.
·
Journal of Hematology & Oncology
·
64
PDF
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
2020
·
Giovanna Garufi
, Antonella Palazzo
, et al.
·
Expert Opinion on Pharmacotherapy
·
63
HOX gene methylation status analysis in patients with hereditary breast cancer
2012
·
Brunella Pilato
, Rosamaria Pinto
, et al.
·
Journal of Human Genetics
·
61
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
2021
·
Sophie E. Willis
, Claudia Winkler
, et al.
·
British Journal of Cancer
·
60
PDF
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials
2020
·
Jiatao Hao
, Ying Liu
, et al.
·
Critical Reviews in Oncology/Hematology
·
60
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
2020
·
Ilary Ruscito
, Filippo Bellati
, et al.
·
Cancer Treatment Reviews
·
60
Show more works
View as search
Works count:
524
Citation count:
8,420
Year
Topic
Type